Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

337
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
337
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

225
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
225
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

272
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
272
Model Approaches for Pharmacokinetic Data: Physiological Models01:15

Model Approaches for Pharmacokinetic Data: Physiological Models

309
Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
309
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

256
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
256
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

393
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
393

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Open Systems Pharmacology Community Conference (OSP-CC) Proceedings 2025.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Development of a Physiologically Based Model of Bilirubin Metabolism in Health and Disease and Its Comparison With Real-World Data.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Foundational Principles for the Quantitative Translation of T-Cell Therapeutics for Hematologic Malignancies and Immunology.

Clinical pharmacology and therapeutics·2025
Same author

A comparative computational analysis of IFN-alpha pharmacokinetics and its induced cellular response in mice and humans.

PLoS computational biology·2025
Same author

Harnessing Open-Source Solutions: Insights From the First Open Systems Pharmacology (OSP) Community Conference.

CPT: pharmacometrics & systems pharmacology·2025
Same author

Evaluation of BCRP-Related DDIs Between Methotrexate and Cyclosporin A Using Physiologically Based Pharmacokinetic Modelling.

Drugs in R&D·2024

Related Experiment Video

Updated: Feb 22, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

5.4K

Comprehensive Pathophysiology Repository for PBPK Modeling in Liver Cirrhosis: Quantifying Continuous Disease

Annika R P Schneider1,2, Vanessa Baier1,3, Jan-Frederik Schlender2,4

  • 1Institute of Applied Microbiology - iAMB, Aachen Biology and Biotechnology - ABBt, RWTH Aachen University, Aachen, Germany.

CPT: Pharmacometrics & Systems Pharmacology
|February 20, 2026
PubMed
Summary
This summary is machine-generated.

This study developed a comprehensive repository of physiological changes in liver cirrhosis patients. This resource enhances pharmacokinetic (PK) modeling, improving drug development and clinical trial design for this complex patient population.

Keywords:
Child‐Pugh scorePBPK modelinghepatic impairmentliver cirrhosispharmacokinetics

More Related Videos

Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats
09:37

Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats

Published on: August 1, 2018

15.5K
Rat Model of the Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy ALPPS Procedure
07:29

Rat Model of the Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy ALPPS Procedure

Published on: August 14, 2017

15.5K

Related Experiment Videos

Last Updated: Feb 22, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

5.4K
Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats
09:37

Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats

Published on: August 1, 2018

15.5K
Rat Model of the Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy ALPPS Procedure
07:29

Rat Model of the Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy ALPPS Procedure

Published on: August 14, 2017

15.5K

Area of Science:

  • Pharmacokinetics and Drug Metabolism
  • Systems Biology and Computational Modeling
  • Clinical Pharmacology in Liver Disease

Background:

  • Liver cirrhosis causes complex pharmacokinetic (PK) alterations due to changes in absorption, distribution, metabolism, and excretion (ADME).
  • Existing repositories for cirrhosis pathophysiology offer limited data, hindering precise PK modeling and clinical applicability.
  • Physiologically based pharmacokinetic (PBPK) modeling requires quantified physiological changes for accurate drug PK prediction in specific populations.

Purpose of the Study:

  • To develop a repository quantifying physiological alterations throughout cirrhosis progression, including population variability.
  • To incorporate parameters for physiological changes not previously included in existing repositories.
  • To enhance the accuracy and clinical utility of PBPK models for liver cirrhosis patients.

Main Methods:

  • A Markov-Chain-Monte-Carlo (MCMC) approach was used to process heterogeneous data and population variability.
  • Data were aggregated from 68 literature studies (216,609 data points) and the IBM Explorys EHR database (208,851 patients).
  • The developed repository includes 30 quantified physiological parameters reflecting cirrhosis progression.

Main Results:

  • The repository successfully quantifies mean changes and population variability in 30 physiological parameters across cirrhosis progression.
  • Integration into a PBPK modeling framework demonstrated strong predictive performance, with 96% of predicted PK parameter ratios within a twofold range.
  • The developed repository significantly advances PK modeling capabilities for liver cirrhosis.

Conclusions:

  • The developed repository provides a robust quantification of physiological changes in liver cirrhosis, crucial for PBPK modeling.
  • This resource facilitates improved planning and analysis of clinical studies in cirrhotic patients.
  • The approach supports the advancement towards virtual clinical trials and personalized medicine in liver cirrhosis.